Ronald Natale on How Nurses Contribute to Patients' Quality of Life

Name: Ronald Natale on How Nurses Contribute to Patients' Quality of Life
Uploaded: 2016-09-16T01:44:03.000Z
Description: Oncology nurses are an important resource for patients with cancer when dealing with adverse effects that can be disruptive to quality of life.

September 15, 2016

Ronald Natale, MD

Video

Oncology nurses are an important resource for patients with cancer when dealing with adverse effects that can be disruptive to quality of life.

Ronald Natale, MD, of the Samuel Ocean Comprehensive Cancer Institute at Cedars-Sinai Medical Center, talks about the important role a nurse can play in improving the quality of life of patients with cancer.

When it comes to patients who have an EGRF-mutated lung cancer, adverse effects of the treatment can be annoying more than life-threatening. When it comes to dealing with skin, brittle hair/hair dye, and nail weakness, the oncology nurses become an important resource for patients, especially because many patients are on these therapies for a long time.

Related Content

FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC

April 18th 2024

Article

Alectinib was approved for the treatment of patients with ALK-positive non-small cell lung cancer after surgical resection.

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

November 15th 2023

Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

April 12th 2024

Article

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

A Look Back at 2022 FDA Approvals in Oncology

January 2nd 2023

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Adagrasib Provides Greater Benefit vs Docetaxel in KRAS G12C–Mutant NSCLC

April 9th 2024

Article

Compared with docetaxel, adagrasib improved progression-free survival and objective response rate in patients with pretreated KRAS G12C–mutant non–small cell lung cancer.

TTFields Improves Time to Progression in Brain Metastases From NSCLC

April 8th 2024

Article

Tumor-treating fields significantly improved the time to intracranial progression in patients from the phase 3 METIS trial with brain metastases from non-small cell lung cancer.

Related Content

FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC

April 18th 2024

Article

Alectinib was approved for the treatment of patients with ALK-positive non-small cell lung cancer after surgical resection.

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

November 15th 2023

Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

April 12th 2024

Article

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

A Look Back at 2022 FDA Approvals in Oncology

January 2nd 2023

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Adagrasib Provides Greater Benefit vs Docetaxel in KRAS G12C–Mutant NSCLC

April 9th 2024

Article

Compared with docetaxel, adagrasib improved progression-free survival and objective response rate in patients with pretreated KRAS G12C–mutant non–small cell lung cancer.

TTFields Improves Time to Progression in Brain Metastases From NSCLC

April 8th 2024

Article

Tumor-treating fields significantly improved the time to intracranial progression in patients from the phase 3 METIS trial with brain metastases from non-small cell lung cancer.